Adaptive Biotechnologies Corporation
Organization details
- Legal name
- Adaptive Biotechnologies Corporation
- Former names
- Adaptive TCR Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Washington
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ADPT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001478320
- EIN
- 27-0907024
- Wikidata ID
- Q30283420
Board of directors
-
Chad M. Robins · Director · CEO and ChairmanSince 2023
-
Katey Einterz Owen · DirectorSince 2023
-
Kevin T. Conroy · DirectorSince 2023
-
Leslie Trigg · DirectorSince 2023
-
Michael J. Pellini · DirectorSince 2023
-
Michelle Renee Griffin · DirectorSince 2023
-
Peter M. Neupert · DirectorSince 2023
-
Robert Hershberg · DirectorSince 2023
Chief executives
Board connections
4 of this board's directors also sit on 9 other boards. 7 are in the same sector.
-
Abbott Laboratories Same sectorvia Kevin T. Conroy
-
Align Technology Inc. Same sectorvia Kevin T. Conroy
- via Kevin T. Conroy
- via Robert Hershberg
-
Fate Therapeutics Inc. Same sectorvia Robert Hershberg
-
Fortrea Holdings Inc. Same sectorvia Peter M. Neupert
-
Labcorp Holdings Inc. Same sectorvia Peter M. Neupert
-
Outset Medical Inc. Same sectorvia Leslie Trigg
-
Recursion Pharmaceuticals Inc. Same sectorvia Robert Hershberg
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $130,569,658
- 180 sales by 11 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 10, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Option exercise | +11,881 | $12.14 | $144,235 |
| Nov 10, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −9,981 | $29.35 | $292,942 |
| Nov 10, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −1,900 | $30.41 | $57,779 |
| Nov 9, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Option exercise | +11,881 | $12.14 | $144,235 |
| Nov 9, 2026 | Chad M. Robins Director, Officer (CEO and Chairman) | Gift | −100,000 | — | — |
| Nov 9, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −1,100 | $28.87 | $31,757 |
| Nov 9, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −8,381 | $30.15 | $252,687 |
| Nov 9, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −2,400 | $30.58 | $73,392 |
| Nov 6, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Option exercise | +11,881 | $12.14 | $144,235 |
| Nov 6, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −8,400 | $27.32 | $229,488 |
| Nov 6, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −3,481 | $27.88 | $97,050 |
| Nov 5, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Option exercise | +11,881 | $12.14 | $144,235 |
| Nov 5, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −5,926 | $26.10 | $154,669 |
| Nov 5, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −5,455 | $26.88 | $146,630 |
| Nov 5, 2026 | RUBINSTEIN JULIE Officer (President and COO) | Open-market sale | −500 | $27.70 | $13,850 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Adaptive Biotechnologies Corporation
Who is the CEO of Adaptive Biotechnologies Corporation?
Chad M. Robins is Adaptive Biotechnologies Corporation's CEO and Chairman.
How many directors are on Adaptive Biotechnologies Corporation's board?
Adaptive Biotechnologies Corporation's board has 8 directors: Chad M. Robins, Katey Einterz Owen, Kevin T. Conroy, Leslie Trigg, Michael J. Pellini, Michelle Renee Griffin, Peter M. Neupert and Robert Hershberg.
Are Adaptive Biotechnologies Corporation insiders buying or selling shares?
Over the last 12 months, Adaptive Biotechnologies Corporation insiders made no open-market purchases and sold $130.6 million of shares in 180 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="adaptive-biotechnologies-corporation"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.